386 related articles for article (PubMed ID: 28130349)
1. Optic disc haemorrhages at baseline as a risk factor for poor outcome in the Idiopathic Intracranial Hypertension Treatment Trial.
Wall M; Thurtell MJ;
Br J Ophthalmol; 2017 Sep; 101(9):1256-1260. PubMed ID: 28130349
[TBL] [Abstract][Full Text] [Related]
2. The Relationship Between Optic Disc Volume, Area, and Frisén Score in Patients With Idiopathic Intracranial Hypertension.
Sheils CR; Fischer WS; Hollar RA; Blanchard LM; Feldon SE;
Am J Ophthalmol; 2018 Nov; 195():101-109. PubMed ID: 30081012
[TBL] [Abstract][Full Text] [Related]
3. Papilledema Outcomes from the Optical Coherence Tomography Substudy of the Idiopathic Intracranial Hypertension Treatment Trial.
;
Ophthalmology; 2015 Sep; 122(9):1939-45.e2. PubMed ID: 26198807
[TBL] [Abstract][Full Text] [Related]
4. Anatomic and visual function outcomes in paediatric idiopathic intracranial hypertension.
Gospe SM; Bhatti MT; El-Dairi MA
Br J Ophthalmol; 2016 Apr; 100(4):505-9. PubMed ID: 26269534
[TBL] [Abstract][Full Text] [Related]
5. Optic nerve appearance as a predictor of visual outcome in patients with idiopathic intracranial hypertension.
Micieli JA; Bruce BB; Vasseneix C; Blanch RJ; Berezovsky DE; Peragallo JH; Newman NJ; Biousse V
Br J Ophthalmol; 2019 Oct; 103(10):1429-1435. PubMed ID: 30530819
[TBL] [Abstract][Full Text] [Related]
6. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.
; Wall M; McDermott MP; Kieburtz KD; Corbett JJ; Feldon SE; Friedman DI; Katz DM; Keltner JL; Schron EB; Kupersmith MJ
JAMA; 2014 Apr 23-30; 311(16):1641-51. PubMed ID: 24756514
[TBL] [Abstract][Full Text] [Related]
7. Factors Affecting Visual Field Outcomes in the Idiopathic Intracranial Hypertension Treatment Trial.
Cello KE; Keltner JL; Johnson CA; Wall M;
J Neuroophthalmol; 2016 Mar; 36(1):6-12. PubMed ID: 26618282
[TBL] [Abstract][Full Text] [Related]
8. Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part II: correlations and relationship to clinical features.
; Auinger P; Durbin M; Feldon S; Garvin M; Kardon R; Keltner J; Kupersmith MJ; Sibony P; Plumb K; Wang JK; Werner JS
Invest Ophthalmol Vis Sci; 2014 Nov; 55(12):8173-9. PubMed ID: 25370513
[TBL] [Abstract][Full Text] [Related]
9. OCT measurements of optic nerve head changes in idiopathic intracranial hypertension.
Huang-Link YM; Al-Hawasi A; Oberwahrenbrock T; Jin YP
Clin Neurol Neurosurg; 2015 Mar; 130():122-7. PubMed ID: 25614195
[TBL] [Abstract][Full Text] [Related]
10. Segmentation error in spectral domain optical coherence tomography measures of the retinal nerve fibre layer thickness in idiopathic intracranial hypertension.
Aojula A; Mollan SP; Horsburgh J; Yiangou A; Markey KA; Mitchell JL; Scotton WJ; Keane PA; Sinclair AJ
BMC Ophthalmol; 2018 Jan; 17(1):257. PubMed ID: 29298687
[TBL] [Abstract][Full Text] [Related]
11. Peripapillary Retinal Pigment Epithelium Layer Shape Changes From Acetazolamide Treatment in the Idiopathic Intracranial Hypertension Treatment Trial.
Wang JK; Kardon RH; Ledolter J; Sibony PA; Kupersmith MJ; Garvin MK;
Invest Ophthalmol Vis Sci; 2017 May; 58(5):2554-2565. PubMed ID: 28492874
[TBL] [Abstract][Full Text] [Related]
12. Effect of optic nerve sheath fenestration for idiopathic intracranial hypertension on retinal nerve fiber layer thickness.
Starks V; Gilliland G; Vrcek I; Gilliland C
Orbit; 2016; 35(2):87-90. PubMed ID: 26928128
[TBL] [Abstract][Full Text] [Related]
13. Weight reduction for a better visual outcome in idiopathic intracranial hypertension.
Koc F; Isik MR; Sefi-Yurdakul N
Arq Bras Oftalmol; 2018; 81(1):18-23. PubMed ID: 29538589
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension.
Wall M; Falardeau J; Fletcher WA; Granadier RJ; Lam BL; Longmuir RA; Patel AD; Bruce BB; He H; McDermott MP;
Neurology; 2015 Sep; 85(9):799-805. PubMed ID: 26245929
[TBL] [Abstract][Full Text] [Related]
15. Safety and Tolerability of Acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial.
ten Hove MW; Friedman DI; Patel AD; Irrcher I; Wall M; McDermott MP;
J Neuroophthalmol; 2016 Mar; 36(1):13-9. PubMed ID: 26587993
[TBL] [Abstract][Full Text] [Related]
16. Retinal vessel diameter changes after 6 months of treatment in the Idiopathic Intracranial Hypertension Treatment Trial.
Moss HE; Hollar RA; Fischer WS; Feldon SE
Br J Ophthalmol; 2020 Oct; 104(10):1430-1434. PubMed ID: 31949093
[TBL] [Abstract][Full Text] [Related]
17. Surgically induced changes in retinal vessel diameter, retinal nerve fibre layer thickness, and the optic disc after 23-gauge pars plana vitrectomy.
Lee SU; Nam KY; Lee SJ
Int Ophthalmol; 2017 Jun; 37(3):575-581. PubMed ID: 27492729
[TBL] [Abstract][Full Text] [Related]
18. Optic disc progression and rates of visual field change in treated glaucoma.
De Moraes CG; Liebmann JM; Park SC; Teng CC; Nemiroff J; Tello C; Ritch R
Acta Ophthalmol; 2013 Mar; 91(2):e86-91. PubMed ID: 23356423
[TBL] [Abstract][Full Text] [Related]
19. Long-term visual outcome in a Danish population of patients with idiopathic intracranial hypertension.
Hatem CF; Yri HM; Sørensen AL; Wegener M; Jensen RH; Hamann S
Acta Ophthalmol; 2018 Nov; 96(7):719-723. PubMed ID: 29405582
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Treatment of Idiopathic Intracranial Hypertension on Prevalence of Retinal and Choroidal Folds.
Kupersmith MJ; Sibony PA; Feldon SE; Wang JK; Garvin M; Kardon R;
Am J Ophthalmol; 2017 Apr; 176():77-86. PubMed ID: 28040526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
